Pacific Biosciences of California (NASDAQ:PACB) reported earnings of ($0.17) per share meeting Walls Streets expectations.

ME Staff
-
0

Pacific Biosciences of California (NASDAQ:PACB) reported Q2 2018 earnings this Afternoon, coming in at ($0.17) per share, in-line Wall Street’s estimates of ($0.17) per Share. Revenue for the quarter came in at $21.58 million missing the streets estimates of $24.45 million

Recent Insider Trading for Pacific Biosciences of California (NASDAQ:PACB)

  • On 10/28/2016 James Michael Phillips, SVP, sold 20,000 with an average share price of $8.44 per share and the total transaction amounting to $168,800.00.
  • On 7/29/2016 James Michael Phillips, SVP, sold 20,000 with an average share price of $8.45 per share and the total transaction amounting to $169,000.00.
  • On 4/25/2016 James Michael Phillips, SVP, sold 20,000 with an average share price of $10.29 per share and the total transaction amounting to $205,800.00.
  • On 3/2/2015 Brian B Dow, VP, bought 2,503 with an average share price of $4.91 per share and the total transaction amounting to $12,289.73.
  • On 3/2/2015 Kevin P Corcoran, SVP, bought 2,816 with an average share price of $4.91 per share and the total transaction amounting to $13,826.56.
  • On 8/19/2014 William W Ericson, Director, bought 39,299 with an average share price of $5.14 per share and the total transaction amounting to $201,996.86.



    About Company
    Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.

    Recent Analyst Rating for Pacific Biosciences of California (NASDAQ:PACB)



      Recent Trading for Pacific Biosciences of California (NASDAQ:PACB)
      Shares of Pacific Biosciences of California closed the previous trading session at 3.88 up +0.090 2.37% with 607000 shares trading hands.